IFNA1 and neoplasm: For a decade, interferon biology has framed ICI responsiveness: tumor-intrinsic IFN/IFN-γ signatures track with benefit, whereas defects in antigen presentation and JAK–STAT signaling herald resistance; however, chronic interferon programs can reinforce adaptive resistance.